Abstract:Background Elevated concentrations of low-density lipoprotein cholesterol (LDL-c) and low grade vascular inflammation, commonly quantified using high-sensitivity C-reactive protein (hsCRP), have been demonstrated to be causal in the development of atherosclerotic disease. Whilst recent large-scale trials have investigated the relative impact of LDL-c and inflammation on cardiovascular outcomes, there is a scarcity of data in real-world patients undergoing percutaneous coronary intervention (PCI). Purpose To investigate the relative drivers of residual risk in patients with established statin treatment undergoing PCI in a contemporary large-scale cohort. Methods From January 2012 to February 2020 patients undergoing PCI at a tertiary center were included for current analysis. Patients were categorized into 4 subgroups according to different combinations of LDL-c and hsCRP concentrations at baseline: no residual cholesterol or inflammatory risk (LDL-c <70 mg/dL + hsCRP <2 mg/L), residual cholesterol risk (LDL-c ≥70 mg/dL + hsCRP <2 mg/L), residual inflammatory risk (LDL-c 10 mg/l were excluded. The outcome of interest was major adverse cardiac events (MACE - composite of all-cause mortality, myocardial infarction, or stroke). A univariable cox regression model was calculated. Results Overall, 10,845 patients were included. In total, 3,210 patients displayed neither cholesterol nor inflammatory risk and 3,059 individuals had elevated cholesterol risk only. In 1,839 patients an inflammatory risk was noted, whilst 2,737 patients presented with combined cholesterol and inflammatory risk. Kaplan-Meier curves for 1-year follow-up are displayed in Figure 1. Patients with residual inflammatory risk had the highest event rate of the composite endpoint (5.2%), followed by patients with combined residual risk (3.5%), individuals with residual cholesterol risk (2.3%) and persons with neither cholesterol nor inflammatory risk (2.4%; p<0.0001 for log rank test across all groups). An association with MACE was solely documented for patients with residual inflammatory risk (HR: 2.09, 95% CI: 1.52 - 2.88; p<.001), and also borderline significant for combined cholesterol and inflammatory risk (HR: 1.41, 95% CI: 1.03 - 1.95; p=0.034), whilst this was not the case for patients with elevated cholesterol risk only (see Figure 2). Conclusion In a contemporary real-world cohort of statin treated patients undergoing PCI, inflammation irrespective of LDL-c concentrations was the driver for adverse cardiovascular outcomes. This data might be helpful to further define target populations for both intensified lipid-lowering as well as anti-inflammatory treatment approaches.

The relationship between ceramide profile and residual inflammatory risk in patients with coronary artery disease: Insights from an prospective study

Association Between Non-High-density Lipoprotein Cholesterol and Coronary Artery Disease in Patients with Acute Coronary Syndrome: a Single-Centre Retrospective Cross-Sectional Analysis

Association Between Plasma Ceramides and One-Year Mortality in Patients with Acute Coronary Syndrome: Insight from the PEACP Study

Associations between plasma ceramides and mortality in patients with coronary artery disease

Association between Multiple Inflammatory Biomarkers and Remnant Cholesterol Levels in Patients with Percutaneous Coronary Intervention: A Large-Scale Real-World Study

Ceramide is Upregulated and Associated with Mortality in Patients with Chronic Heart Failure

Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction

Ceramides and metabolic profiles of patients with acute coronary disease: a cross-sectional study

High-Sensitivity CRP is Independently Associated with HDL-Mediated Cholesterol Efflux Capacity and HDL Remodeling in Patients with Coronary Artery Disease

Association between the plasma ceramide and coronary microvascular resistance

Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome

The role of residual inflammatory risk and LDL cholesterol in patients with in-stent restenosis undergoing percutaneous coronary intervention

Associations of HDL-C and ApoA-I with Mortality Risk in PCI Patients Across Different hsCRP Levels

Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study

Prognostic significance of inflammation in patients with coronary artery disease at low residual inflammatory risk

Abnormal plasma ceramides refine high-risk patients with worsening heart failure

Significance of Persistent Inflammation in Patients With Chronic Coronary Syndrome: Insights From the REAL-CAD Study

Ceramide Remodeling and Risk of Cardiovascular Events and Mortality.

The residual risk of inflammation and remnant cholesterol in acute coronary syndrome patients on statin treatment undergoing percutaneous coronary intervention

Ceramides and pro-inflammatory cytokines for the prediction of acute coronary syndrome: a multi-marker approach

Clinical outcomes according to residual cholesterol and inflammatory risk in patients undergoing PCI